Skip to content
Ejaculation.org

Randomised controlled trial · 2019

Which of available selective serotonin reuptake inhibitors (SSRIs) is more effective in treatment of premature ejaculation? A randomized clinical trial

Siroosbakht S, Rezakhaniha S, Rezakhaniha B (2019). Which of available selective serotonin reuptake inhibitors (SSRIs) is more effective in treatment of premature ejaculation? A randomized clinical trial. International Braz J Urol. doi:10.1590/S1677-5538.IBJU.2019.0121

Key finding
In 480 Iranian men with PE randomised to daily sertraline, fluoxetine, paroxetine or citalopram, all four raised latency from about 70–90 s to roughly 280–380 s at 8 weeks, with no significant difference between drugs or in side effects.

Summary

This randomised clinical trial at a hospital in Tehran compared four SSRIs (selective serotonin reuptake inhibitors) for premature ejaculation (PE). In 2018 and 2019, 480 men were assigned to four groups taking sertraline 50 mg, fluoxetine 20 mg, paroxetine 20 mg or citalopram 20 mg every 12 hours. Intravaginal ejaculatory latency time (IELT: the time from penetration to ejaculation) was recorded by the man's wife with a stopwatch.

Mean IELT before treatment and at 8 weeks was 69.4 and 376.3 seconds with sertraline, 75.5 and 314.8 seconds with fluoxetine, 71.5 and 379.9 seconds with paroxetine, and 90.4 and 282.5 seconds with citalopram. Latency rose significantly in every group, with no significant difference between the drugs and no significant difference in side effects. The most common side effects were drowsiness and indigestion, which did not lead anyone to stop.

Limitations

There was no placebo group, and the abstract does not describe blinding. All drugs were taken twice daily, which gives higher total daily doses than many doctors start with. Follow-up was 8 weeks at a single centre, and other analyses, such as Waldinger et al. (2004), have found paroxetine somewhat stronger than the others.

What it means for you

The common daily SSRIs all delayed ejaculation substantially in this trial, and none clearly beat the others. If one does not suit you, a doctor may suggest another, which is what the authors recommend.